Lara Bull–Otterson

2.7k total citations · 4 hit papers
24 papers, 1.6k citations indexed

About

Lara Bull–Otterson is a scholar working on Infectious Diseases, Epidemiology and Clinical Psychology. According to data from OpenAlex, Lara Bull–Otterson has authored 24 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Infectious Diseases, 5 papers in Epidemiology and 4 papers in Clinical Psychology. Recurrent topics in Lara Bull–Otterson's work include COVID-19 Clinical Research Studies (7 papers), COVID-19 and healthcare impacts (4 papers) and HIV Research and Treatment (3 papers). Lara Bull–Otterson is often cited by papers focused on COVID-19 Clinical Research Studies (7 papers), COVID-19 and healthcare impacts (4 papers) and HIV Research and Treatment (3 papers). Lara Bull–Otterson collaborates with scholars based in United States. Lara Bull–Otterson's co-authors include Tegan K. Boehmer, Aaron M. Harris, Sharon Saydah, Sarah Baca, Stacey Adjei, Simone C. Gray, Adi V. Gundlapalli, Lu‐Yu Hwang, Swati Joshi‐Barve and Craig J. McClain and has published in prestigious journals such as PLoS ONE, Hepatology and Clinical Infectious Diseases.

In The Last Decade

Lara Bull–Otterson

22 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Metagenomic Analyses of Alcohol Induced Pathogenic Alterations in the Intestinal Microbiome and the Effect of Lactobacillus rhamnosus GG Treatment

2013 432 citations Lara Bull–Otterson, Wenke Feng et al. PLoS ONE profile →
Post–COVID Conditions Among Adult COVID-19 Survivors Aged 18–64 and ≥65 Years — United States, March 2020–November 2021

2022 220 citations Lara Bull–Otterson, Sarah Baca et al. MMWR Morbidity and Mortality Weekly Report profile →
Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years — United States, March 1, 2020–June 28, 2021

2022 175 citations Catherine Barrett, Alain K. Koyama et al. MMWR Morbidity and Mortality Weekly Report profile →
Post–COVID-19 Symptoms and Conditions Among Children and Adolescents — United States, March 1, 2020–January 31, 2022

2022 100 citations Lyudmyla Kompaniyets, Lara Bull–Otterson et al. MMWR Morbidity and Mortality Weekly Report profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lara Bull–Otterson United States	16	619	549	343	335	209	24	1.6k
Giustino Parruti Italy	26	793 1.3×	649 1.2×	173 0.5×	622 1.9×	85 0.4×	144	2.4k
Clara Lehmann Germany	25	1.4k 2.2×	611 1.1×	196 0.6×	348 1.0×	87 0.4×	122	3.2k
Esperanza Merino Spain	20	736 1.2×	532 1.0×	507 1.5×	137 0.4×	45 0.2×	123	1.7k
Vicente Boix Spain	18	741 1.2×	358 0.7×	496 1.4×	107 0.3×	74 0.4×	91	1.6k
Patrick Mallon Ireland	38	2.2k 3.6×	804 1.5×	138 0.4×	438 1.3×	160 0.8×	198	4.2k
Stefano Zona Italy	28	1.3k 2.2×	1.4k 2.6×	144 0.4×	223 0.7×	192 0.9×	85	3.6k
Katharine A. Kirby United States	25	1.0k 1.7×	1.5k 2.7×	220 0.6×	199 0.6×	53 0.3×	54	2.8k
Weina Guo China	15	910 1.5×	272 0.5×	430 1.3×	275 0.8×	27 0.1×	29	1.6k
Roberto Muga Spain	24	595 1.0×	1.2k 2.2×	79 0.2×	62 0.2×	266 1.3×	128	2.3k
Andrea Calcagno Italy	27	1.6k 2.6×	621 1.1×	77 0.2×	249 0.7×	76 0.4×	229	2.8k

Countries citing papers authored by Lara Bull–Otterson

Since Specialization

Citations

This map shows the geographic impact of Lara Bull–Otterson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lara Bull–Otterson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lara Bull–Otterson more than expected).

Fields of papers citing papers by Lara Bull–Otterson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lara Bull–Otterson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lara Bull–Otterson. The network helps show where Lara Bull–Otterson may publish in the future.

Co-authorship network of co-authors of Lara Bull–Otterson

This figure shows the co-authorship network connecting the top 25 collaborators of Lara Bull–Otterson. A scholar is included among the top collaborators of Lara Bull–Otterson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lara Bull–Otterson. Lara Bull–Otterson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kamdar, Neil, David H. Rehkopf, Sharon Saydah, et al.. (2024). Post-COVID Conditions in US Primary Care: A PRIME Registry Comparison of Patients With COVID-19, Influenza-Like Illness, and Wellness Visits. The Annals of Family Medicine. 22(4). 279–287.

Kompaniyets, Lyudmyla, Ryan E. Wiegand, Lara Bull–Otterson, et al.. (2023). Relative Effectiveness of Coronavirus Disease 2019 Vaccination and Booster Dose Combinations Among 18.9 Million Vaccinated Adults During the Early Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Period—United States, 1 January 2022 to 31 March 2022. Clinical Infectious Diseases. 76(10). 1753–1760. 7 indexed citations

Yuan, Yan, JoAnn M. Thierry, Lara Bull–Otterson, et al.. (2022). COVID-19 Cases and Hospitalizations Among Medicare Beneficiaries With and Without Disabilities — United States, January 1, 2020–November 20, 2021. MMWR Morbidity and Mortality Weekly Report. 71(24). 791–796. 14 indexed citations

Bull–Otterson, Lara, Sarah Baca, Sharon Saydah, et al.. (2022). Post–COVID Conditions Among Adult COVID-19 Survivors Aged 18–64 and ≥65 Years — United States, March 2020–November 2021. MMWR Morbidity and Mortality Weekly Report. 71(21). 713–717. 220 indexed citations breakdown →

Barrett, Catherine, Alain K. Koyama, Pablo Álvarez, et al.. (2022). Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years — United States, March 1, 2020–June 28, 2021. MMWR Morbidity and Mortality Weekly Report. 71(2). 59–65. 175 indexed citations breakdown →

Kompaniyets, Lyudmyla, Lara Bull–Otterson, Tegan K. Boehmer, et al.. (2022). Post–COVID-19 Symptoms and Conditions Among Children and Adolescents — United States, March 1, 2020–January 31, 2022. MMWR Morbidity and Mortality Weekly Report. 71(31). 993–999. 100 indexed citations breakdown →

Adjei, Stacey, Kai Hong, Noelle‐Angelique Molinari, et al.. (2022). Mortality Risk Among Patients Hospitalized Primarily for COVID-19 During the Omicron and Delta Variant Pandemic Periods — United States, April 2020–June 2022. MMWR Morbidity and Mortality Weekly Report. 71(37). 1182–1189. 106 indexed citations

Kaufman, Harvey W., Lara Bull–Otterson, William A. Meyer, et al.. (2021). Decreases in Hepatitis C Testing and Treatment During the COVID-19 Pandemic. American Journal of Preventive Medicine. 61(3). 369–376. 60 indexed citations

Rodgers, Loren, Michael Sheppard, Amanda R. Smith, et al.. (2021). Changes in Seasonal Respiratory Illnesses in the United States During the Coronavirus Disease 2019 (COVID-19) Pandemic. Clinical Infectious Diseases. 73(Supplement_1). S110–S117. 89 indexed citations

10.

Bull–Otterson, Lara, Elizabeth B. Gray, Daniel S. Budnitz, et al.. (2020). Hydroxychloroquine and Chloroquine Prescribing Patterns by Provider Specialty Following Initial Reports of Potential Benefit for COVID-19 Treatment — United States, January–June 2020. MMWR Morbidity and Mortality Weekly Report. 69(35). 1210–1215. 47 indexed citations

11.

Bull–Otterson, Lara, et al.. (2020). Human Immunodeficiency Virus and Hepatitis C Virus Infection Testing Among Commercially Insured Persons Who Inject Drugs, United States, 2010–2017. The Journal of Infectious Diseases. 222(6). 940–947. 31 indexed citations

12.

Owusu‐Edusei, Kwame, et al.. (2019). County-Level Social Capital and Bacterial Sexually Transmitted Infections in the United States. Sexually Transmitted Diseases. 47(3). 165–170. 8 indexed citations

13.

Bull–Otterson, Lara, Wenke Feng, Irina Kirpich, et al.. (2013). Metagenomic Analyses of Alcohol Induced Pathogenic Alterations in the Intestinal Microbiome and the Effect of Lactobacillus rhamnosus GG Treatment. PLoS ONE. 8(1). e53028–e53028. 432 indexed citations breakdown →

14.

Arora, Reetakshi, Lara Bull–Otterson, Edward B. Siwak, et al.. (2010). Dendritic Cell–Mediated HIV-1 Infection of T Cells Demonstrates a Direct Relationship to Plasma Viral RNA Levels. JAIDS Journal of Acquired Immune Deficiency Syndromes. 54(2). 115–121. 4 indexed citations

15.

Reeves, Will K., et al.. (2008). Serological evidence of typhus group rickettsia in a homeless population in Houston, Texas. Journal of Vector Ecology. 33(1). 205–207. 24 indexed citations

16.

Meyer, Tamra E., et al.. (2007). West Nile Virus Infection among the Homeless, Houston, Texas1. Emerging infectious diseases. 13(10). 1500–1503. 25 indexed citations

17.

Lee, Seung‐Jae, Reetakshi Arora, Lara Bull–Otterson, et al.. (2006). A Nonneutralizing Anti-HIV Type 1 Antibody Turns into a Broad Neutralizing Antibody When Expressed on the Surface of HIV Type 1-Susceptible Cells. II. Inhibition of HIV Type 1 Captured and Transferred by DC-SIGN. AIDS Research and Human Retroviruses. 22(9). 874–883. 4 indexed citations

18.

Hwang, Lu‐Yu, Jennifer R. Kramer, Catherine Troisi, et al.. (2006). Relationship of cosmetic procedures and drug use to hepatitis C and hepatitis B virus infections in a low-risk population. Hepatology. 44(2). 341–351. 35 indexed citations

19.

Ross, Michael W., et al.. (2002). Sexual risk behaviours and STIs in drug abuse treatment populations whose drug of choice is crack cocaine. International Journal of STD & AIDS. 13(11). 769–774. 69 indexed citations

20.

Hwang, Lu‐Yu, et al.. (2000). Prevalence of Sexually Transmitted Infections and Associated Risk Factors among Populations of Drug Abusers. Clinical Infectious Diseases. 31(4). 920–926. 102 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact